This website uses cookies. By using the site you are agreeing to our Privacy Policy.

HOME >> Company >> Message from the President


Message from the President

Ken-ichiro HataJapan Tissue Engineering Co., Ltd. (J-TEC) was established in February 1999 to develop a business in the field of regenerative medicine using tissue engineering technology. Regenerative medicine is a new branch of medicine that aims to regenerate lost tissue and organs and ultimately restore biological functions utilizing human cells. J-TEC aims to provide high-quality and safe cell-based products. In the process of providing innovative products, it is essential not only to have medical and biological approaches, but also to clear the underlying legal and ethical challenges and ensure the success of regenerative medicine as a new business. J-TEC aims to make regenerative medicine common practice in treating patients, and is moving steadily toward its goal, one step at a time.

J-TEC’s autologous cultured epidermis JACE is the first domestic regenerative medical product utilizing human cell and tissue approved in 2007, and the autologous cultured cartilage JACC is the second regenerative medicine product approved in 2012. J-TEC has been delivering the regenerative medical products to patients for over 10 years, and has established this new business model through possessing all of the functions including research and development, regulatory development, manufacturing, sales, and post-marketing surveillance. Also, J-TEC became a member of the Fujifilm Group in 2014. Leveraging the collective capabilities of the Fujifilm Group, J-TEC will actively explore the development of new, innovative tissue-engineered medical products. Our goal is to contribute to the industrialization of regenerative medicine not only in Japan, but also on a global scale.

We at J-TEC intend to continue growing as a company as long as the human race exists. Our philosophy is to develop a business that will transform the face of medicine in the 21st century, and achieve greater wellbeing for all our stakeholders as a result.

June 26, 2020
Kenichiro Hata

Ken-ichiro Hata
President & CEO